CytoReason is a tech company transforming biopharma’s decision-making from trial and error to data-driven using an AI Platform of computational disease models.
Joined February 2018
- Tweets 583
- Following 1,092
- Followers 662
- Likes 311
143 Photos and videos
May 24
Strong AI and biology capabilities tend to pull companies in one direction.
They build pipelines and develop drugs. They become the competition.
We chose a different path.
CytoReason was built to help pharma make better decisions, not to replace pharma.
We will never develop drugs. That's not a loophole. It's a deliberate design choice.
55
Apr 21
Most Phase II failures aren’t random.
They’re driven by molecular signals that are visible early in development.
Pharma generates enormous amounts of data, yet decisions still rely on fragmented views of biology.
The gap isn’t more data.
It’s turning molecular signals into a system you can actually decide with.
6
30
152
3,279,574
Apr 3
Biopharma doesn’t have a data problem. It has a decision problem.
Billions go into generating data, but critical R&D decisions still rely on fragmented views of biology.
What’s missing is a way to turn biology into something researchers can trust.
The winners won’t be the ones who collect more data. They’ll be the ones who know what to do with it.
40
160
2,130
19,640,869
Mar 24
Everyone is building an AI platform.
That’s not the hard part.
The hard part is keeping it grounded in human biology as new data comes in.
Models can improve on paper while drifting from biological reality.
The platforms that stay anchored in real biology are the ones that hold up, and drive better decisions over time.
5
212,252
Mar 24
Everyone is building an AI platform.
That’s not the hard part.
The hard part is keeping it grounded in human biology as new data comes in.
Models can improve on paper while drifting from biological reality.
The platforms that stay anchored in real biology are the ones that hold up, and drive better decisions over time.
1
12
241,658
Feb 15
Indication selection is a portfolio decision.
The right disease–target pairing can shift probability of success and portfolio value by hundreds of millions of dollars.
CytoReason models disease biology to compare options side by side, earlier in development.
1
179
Feb 9
CytoReason expands collaboration with @sanofi to advance AI-driven drug development.
Grateful for the trust and partnership as we deepen use of disease models in pharma R&D.
Full press release 👇
tinyurl.com/h4he5cph
1
121
Feb 5
CytoReason launches LINA, the first AI agent grounded in molecular data. LINA wasn’t built to make decisions for you. It was built to bring biological clarity into the moments when you have to decide.
Read the press release 👇
cytoreason.com/resources/cyt…
1
243
13 Oct 2024
CytoReason is #hiring.
We're looking for #backend and #fullstack developers, #bioinformaticians, #immunologists and more.
Find out more and apply here:
cytoreason.com/career/?coref…
2
439
18 Aug 2024
Tania Dubovik Perets with Elina Starosvetsky, Yasmin Admon, Shai @shenorr & others publish groundbreaking study showing immune system’s adaptability and providing evidence that interactions between immune cell types facilitate evolution of immune traits.
tinyurl.com/4k9d4b34
4
275
21 Jul 2024
CytoReason raises $80M in Series B from @nvidia, @pfizer, @thermofisher and others. This means we'll be able to cover more sub-populations, strengthen precision of our disease models and empower more decision-makers with AI tools for their R&D.
tinyurl.com/58vmz9vv
2
2,202
23 May 2024
Read more about CytoReason's new data collaboration agreement with @CrohnsColitisFn. We'll be integrating the foundation's vast datasets with CytoReason’s #IBD disease models. Read more about it here:
cytoreason.com/resources/cyt…
2
194
19 May 2024
@Cytoreason signs data collaboration with @CrohnsColitisFn Foundation to advance IBD. We'll be incorporating CCF's massive datasets - with thousands of patient intestinal biopsies and comprehensive real-world data - into our pre-computed disease models.
info.cytoreason.com/ccf
2
161
22 Mar 2024
New episode of "Tech on Drugs" with Prof. Eran Segal from Weizmann and co-founder Prof. Shai @shenorr - addressing precision nutrition, large-scale longitudinal data, microbiome studies, and more.
Fulle episode here: cytoreason.com/podcast/
1
174
10 Mar 2024
In 2023 - 21 CytoReason employees, published 19 papers in 16 different publications - Nature Immunology, Nature Cancer, Nature Communications, Nucleic Acids Research, CellReports, &more.
More here:
tinyurl.com/25ax2hhh #Immunology #pharma
@CellReports
@NAR_Open
3
201
21 Feb 2024
Interview with CEO David Harel about some of the major scientific and commercial challenges our industry faces, and about one tech company's attempt to make things (a little bit) better.
nocamels.com/2024/02/using-a…
1
2
169
7 Feb 2024
Proud of our Chief Scientist Shai @shenorr for contributing to this new study by Benguigui & Cooper et. al, now published in Cancer Cell and highlighted in Nature Reviews Immunology.
cell.com/cancer-cell/fulltex…
#CancerResearch #Oncology
2
3
184
24 Dec 2023
Our team's research published in @CellReports. Introducing 'Disruption Networks', a personalized computational network framework for system-level understanding of disease mechanisms & drug response, exposing differential regulation @ individual level.
tinyurl.com/3kxja5xw
3
4
167